FDA Declares Tirzepatide Shortage Resolved, Tightening Rules for Compounding Pharmacies
Wednesday, June 10th, 2026 - The U.S. Food and Drug Administration has determined that the national shortage of tirzepatide injection, a dual GIP/GLP-1 receptor agonist used for type 2 diabetes and weight management, has been resolved, according to an update posted by the agency's Center for Drug Evaluation and Research. The shortage declaration, first issued in 2022 amid surging demand for incretin-based medicines, had allowed certain compounding pharmacies to produce versions of the drug outside normal regulatory constraints.
Compounding pharmacies face a narrower path
With the shortage officially lifted, the legal window for many compounders to manufacture tirzepatide injections is expected to narrow. Under federal law, pharmacies compounding copies of commercially available, non-shortage drugs face additional scrutiny under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The FDA's compounding inspections and enforcement actions page lists recent compliance activities involving outsourcing facilities and state-licensed pharmacies.
The agency did not immediately publish new warning letters tied specifically to tirzepatide compounding, but its warning-letter database indicates ongoing monitoring of the sector. Industry groups including the Alliance for Pharmacy Compounding and the Outsourcing Facilities Association have previously argued that patient access concerns should weigh in enforcement decisions; neither organization had posted public comment as of publication.
National supply stabilizes after years of strain
Tirzepatide, sold under the brand names Mounjaro and Zepbound, had been listed on the FDA's drug shortages database for nearly four years. The agency's updated determination suggests that manufacturer Eli Lilly and Company has meaningfully increased production capacity, though the company's investor newsroom did not immediately return a status update. Supply constraints earlier in the decade had pushed some patients toward compounded alternatives and prompted federal oversight inquiries, including projects tracked by the Department of Health and Human Services Office of Inspector General.
Clinical pipeline keeps other peptide candidates in view
Trial registrations on ClinicalTrials.gov continue to show active studies involving next-generation incretin agents, including the triple-agonist retatrutide and the fixed-dose combination cagrisema. Preprint servers such as MedRxiv have hosted early-stage analyses of these compounds in recent weeks, though such findings have not undergone peer review. Peer-reviewed journals including the New England Journal of Medicine and JAMA maintain ongoing coverage of incretin clinical data.
Athletes face separate regulatory framework
The World Anti-Doping Agency's prohibited list classifies peptide hormones, growth factors, and related mimetics as restricted substances. WADA's guidance directs athletes to verify current rules directly, as the list is updated annually. Any therapeutic use of tirzepatide or similar peptide-based drugs should be discussed with anti-doping authorities before competition.
